Robert L Wortmann

Learn More
OBJECTIVE To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function. METHODS Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to <(More)
The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. The use of modified uricases to rapidly reduce serum urate concentrations in patients with otherwise untreatable gout is progressing. Additionally, advances in(More)
The effect of the following drugs in therapeutic doses on somatosensory cortical evoked potentials was studied: methamphetamine, chlorpromazine, imipramine, diazepam, phenobarbital, pethidine, and novaminesulfone. Physiological saline was used as control. Each of these compounds was studied in 5 healthy subjects. Three evoked potentials were recorded(More)
  • 1